Why Is Agios Pharmaceuticals (AGIO) Up 25.8% Since Last Earnings Report?Zacks Investment Research • 05/30/20
Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing GliomaGlobeNewsWire • 05/29/20
Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma PatientsGlobeNewsWire • 05/19/20
Agios Pharmaceuticals, Inc.'s (AGIO) CEO Jacqualyn Fouse on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 04/30/20
Agios Pharmaceuticals Shows Improved Relative Strength; Still Shy Of BenchmarkInvestors Business Daily • 04/14/20
Coronavirus Anchor Series: Agios With Strong Cash And 52-Week Low Price Has Good PotentialSeeking Alpha • 04/14/20
Agios Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Mitapivat in Pyruvate Kinase DeficiencyGlobeNewsWire • 03/30/20
Agios Provides Update on 2016 Collaboration Agreement with Celgene, a Wholly Owned Subsidiary of Bristol Myers SquibbGlobeNewsWire • 03/25/20
Agios Announces FDA Clearance of Investigational New Drug Application for AG-946, a Next-Generation PKR ActivatorGlobeNewsWire • 03/23/20
Why Is Agios Pharmaceuticals (AGIO) Down 28.7% Since Last Earnings Report?Zacks Investment Research • 03/14/20
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/13/20
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/13/20
Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 MutationGlobeNewsWire • 12/16/19
Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase DeficiencyGlobeNewsWire • 12/09/19